|Synonyms||PF-04171327; PF-4171327; Dagrocorat 2-(dihydrogen phosphate); Dagrocorat dihydrogen phosphate|
|Drug class||Selective glucocorticoid receptor modulator|
|Chemical and physical data|
|Molar mass||574.537 g/mol g·mol−1|
|3D model (JSmol)|
Fosdagrocorat (developmental code names PF-04171327 and PF-4171327; also known as dagrocorat 2-(dihydrogen phosphate)) is a nonsteroidal but steroid-like selective glucocorticoid receptor modulator (SGRM) which was under development for the treatment of rheumatoid arthritis but was never marketed. It is the C2 dihydrogen phosphate ester of dagrocorat, and acts as a prodrug of dagrocorat with improved pharmacokinetics. The drug reached phase II clinical trials prior to the discontinuation of its development.
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|